General Information
Version
CAT 647 - Lacidipine impurity Standard
Revision date
2024-04-22
Product name
Lacidipine impurity Standard
1.2.1 Relevant identified uses
Laboratory use
supplier name
British Pharmacopoeia Commission
Emergency telephone
+44 (0)20 3080 6561
Icons in SDS
Company Information
company name
British Pharmacopoeia Commission
e-mail address of the competent person responsible for the Safety Data Sheet
bpcrs@mhra.gov.uk
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H302, H315, H319
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 [CLP]] Classification of the substance or mixture Classification according to
Contains
Lacidipine; Ethyl Methyl (E)-4-{ 2-[2-(tert-Butoxycarbonyl) vinyl]phenyl} -1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate
Signal word
Warning
Hazard statements
H302 - Harmful if swallowed H315 - Causes skin irritation H319 - Causes serious eye irritation
Precautionary statements
P264 - Wash face, hands and any exposed skin thoroughly after handling P270 - Do not eat, drink or smoke when using this product P280 - Wear protective gloves and eye/face protection P337 + P313 - If eye irritation persists: Get medical advice/attention P501 - Dispose of contents/ container to an approved waste disposal plant
2.3 Other hazards
No information available. This mixture contains no substance considered to be persistent, bioaccumulating or toxic (PBT). This mixture contains no substance considered to be very persistent nor very bioaccumulating (vPvB). Endocrine Disruptor Information This product does not contain any known or suspected endocrine disruptors. Chemical name
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No. 1272/2008 [CLP] Acute toxicity - Oral Category 4 - (H302) Skin corrosion/irritation Category 2 - (H315) Serious eye damage/eye irritation Category 2 - (H319)
